Who is the manufacturer of Trientine?

Trientine (Trientine) is a copper chelator used to treat Wilson's disease. Its main manufacturer is Bausch Health Companies Inc., a world-renowned pharmaceutical company headquartered in Canada that focuses on the development and production of a variety of pharmaceutical products including rare disease treatment drugs. The company is committed to improving patients' quality of life through innovative medicines and high-quality manufacturing standards.

Trientine is a copper chelator mainly used to treat Wilson's disease (Wilson's disease). Wilson's disease is a rare genetic disorder in which excess copper accumulates in the liver, brain and other organs due to a disorder in copper metabolism, leading to severe liver disease and neurological damage. The active ingredient of Trientine is Trientine Dihydrochloride, which forms a stable complex by combining with copper ions in the body, promoting its excretion, thereby reducing the accumulation of copper in the body. Wilson's disease is a rare genetic disorder caused by abnormalities in copper metabolism that, if not effectively treated, can lead to severe liver disease and neurological damage.

In China, trientine, as a rare disease treatment drug, may be obtained through imported channels. Due to its specific indications and small patient population, the production and supply of trientine often requires close cooperation with the orphan drug supply chain. Chinese patients usually need to get a prescription from a hospital specialist (such as a hepatologist, neurologist or genetic metabolism doctor) and purchase it at the hospital pharmacy or a designated special pharmacy. Some countries or regions may provide rare disease drug assistance programs, and patients can consult relevant medical institutions or rare disease organizations to learn about support and ways to obtain drugs.

Reference materials:https://www.syprine.com/